Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy.
Elisa Yaniz-GalendeQinghe ZengJuan Francisco Grau BejarChristophe KleinFélix Blanc-DurandAudrey Le FormalEric Pujade-LauraineLaure ChardinElodie EdmondVirginie MartyIsabelle L Ray-CoquardFlorence Joly LobbedezGwenaël FerronPatricia PautierDominique Berton-RigaudAlain LortholaryNadine DohollouChristophe DesauwMichel FabbroEmmanuelle MalaurieNathalie Bonichon-LamaichhaneDiana Bello RoufaiJustine GantzerEtienne RouleauCatherine GenestieAlexandra LearyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Several iTMEs exist during tumor evolution and NACT impact on iTME is heterogeneous. Clustering analysis of patients, unravels several IC subsets within OC and can guide future personalized approaches. Targeting different checkpoints such as TIM-3, LAG-3 and IDO-1, more prevalent than PD-L1, could more effectively harness anti-tumor immunity in this anti-PD-L1 resistant malignancy.